Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosis.
Journal: Journal of medical economics
Published: June 21, 2026
Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: December 27, 2025
Proteomic Biomarker Panel for Gauging Multiple Sclerosis Disease Activity: A Case Series From Real-World Use.
Journal: International journal of MS care
Published: March 26, 2025
Real-world clinical utility of a multi-protein, blood-based biomarker assay for disease activity assessments in multiple sclerosis.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: July 29, 2024
Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration.
Journal: Frontiers in aging
Published: June 04, 2023
Correction to: Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
Journal: Journal of neurology
Published: December 27, 2022
Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
Journal: Journal of neurology
Published: June 22, 2022
Showing 1-7 of 7
Last Updated: 09/26/2026